Abstract: The invention relates to methods of (i) treating a subject for a disease, (ii) amelioration of decline of forced vital capacity in a subject in need thereof, (iii) modulating ?V?6 integrin, ?V?1 integrin, or both ?V?6 integrin and ?V?1 integrin in a subject in need thereof, (iv) increasing the expression of one or more genes in a subject in need thereof, (v) decreasing the expression of one or more genes in a subject in need thereof, and (vi) modulating the activity of at least one gene affecting fibrotic activity in a subject in need thereof, comprising administration of compounds of Formula (A), Formula (I), Formula (II), or (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid, or a pharmaceutically acceptable salt thereof as described herein; and administering to the subject at least a second drug selected from pirfenidone and nintedanib, or a salt thereof.

Abstract: A labyrinth seal assembly comprising: an outer seal having a radially inner cavity surface, and an axial cavity surface inward of the radially inner cavity surface; a floating seal received by the outer seal so as to be movable in a radial direction relative to the outer seal, the floating seal having a radially outer seal surface spaced inwardly from the radially inner cavity surface, a radially inner surface inward of the radially outer seal surface, and an axial seal surface bearing against the axial cavity surface; and an inner seal received by the floating seal, the inner seal having a radially outer surface spaced inwardly from the radially inner surface, a first one of the radially outer surface and the radially inner surface defining one tooth projecting toward a second one of the radially outer surface and the radially inner surface to inward of the axial seal surface.

Abstract: A robot-assisted echographic probe that includes an enclosure, an ultrasonic transducer module having a support housing mounted at a distal end of a guide sleeve in a sealed compartment of the enclosure that is separated from a control compartment of the enclosure by a sealed transversal wall, and means for moving the transducer module which are suitable for directing the transducer module along three axes of rotation so as to sweep the inner surface of an enclosure shell of the sealed compartment, the moving means being motor-driven by actuators, at least a portion of the actuators being housed in the control compartment, and the means for moving the transducer module being arranged in the sealed compartment of the enclosure.

Abstract: The invention relates to methods of treating a subject for a disease comprising administration of compounds of Formula (A), Formula (I), or Formula (II): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein; and administering to the subject at least a second drug selected from pirfenidone and nintedanib, or a salt thereof. Compounds of Formula (A), Formula (I), Formula (II), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Abstract: The invention relates to methods of therapy using compounds of formula (I) and formula (II): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (II) and pharmaceutical compositions thereof are integrin inhibitors that are useful in therapy for a condition, for example, caused by or associated with an infectious agent, shock, pancreatitis, or trauma. The condition can include one or more of pulmonary fibrosis associated with rheumatoid arthritis or progressive familial intrahepatic cholestasis (PFIC).

Abstract: The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Abstract: The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Abstract: The present disclosure provides devices for guiding an element in a combustion chamber wall opening. Between the welds or brazes joining a bushing with a cup and the trajectory of the ring edge, an intermediate space is reserved in an internal annular groove for said welds or brazes to protrude into, so that said welds or brazes lie outside the trajectory of the ring edge.

Abstract: The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Abstract: The present disclosure provides devices for guiding an element in a combustion chamber wall opening. Between the welds or brazes joining a bushing with a cup and the trajectory of the ring edge, an intermediate space is reserved in an internal annular groove for said welds or brazes to protrude into, so that said welds or brazes lie outside the trajectory of the ring edge.

Abstract: The present disclosure provides methods of treating fibrosis or a fibrotic disease or condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of cenicriviroc or a salt or solvent thereof. The fibrosis or fibrotic disease may be liver fibrosis, renal fibrosis, non-cirrhotic hepatic fibrosis, associated with non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), or emerging cirrhosis.

Abstract: The disclosure includes the use of cenicriviroc or a salt or solvate thereof and pharmaceutical compositions containing the same in the treatment of inflammation and connective tissue diseases and disorders, such as fibrosis, peritonitis, and liver injury.

Abstract: Cenicriviroc (CVC) is an orally active antagonist of ligand binding to C-C chemokine receptor type 5 (CCR5) and C-C chemokine receptor type 2 (CCR2). CVC blocks the binding of RANTES, MIP-1?, and MIP-1? to CCR5, and of MCP-1/CCL2 to CCR2. Methods of treating fibrosis and related conditions comprising co-administration of CVC with chemokine antagonists, FXR agonists, high dose vitamin E (>400 iU/d), a peroxisome proliferator-activated receptor alpha (PPAR-?) agonist, PPAR-? agonist, and/or PPAR-? agonist are provided herein.

Abstract: Cenicriviroc (CVC) is an orally active antagonist of ligand binding to C-C chemokine receptor type 5 (CCR5) and C-C chemokine receptor type 2 (CCR2). CVC blocks the binding of RANTES. MIP-1?, and MIP-1? to CCR5, and of MCP-1/CCL2 to CCR2. Methods of treating fibrosis and related conditions comprising co-administration of CVC with FXR agonists, high dose vitamin E (>400 iU/d), a peroxisome proliferator-activated receptor alpha (PPAR-?) agonist, PPAR-? agonist, PPAR-? agonist and/or chemokine antagonists are provided herein.

Abstract: A device for converting the wavelength of electromagnetic radiation is disclosed. In an embodiment the device includes a carrier, a conversion layer configured to at least partly convert a wavelength of the electromagnetic radiation and an intermediate layer, wherein the conversion layer is connected to the carrier via the intermediate layer, and wherein the intermediate layer, at least in partial regions, includes a solid layer and a connection layer.

Abstract: The disclosure includes the use of cenicriviroc or a salt or solvate thereof and pharmaceutical compositions containing the same in the treatment of inflammation and connective tissue diseases and disorders, such as fibrosis, peritonitis, and liver injury.

Abstract: The present disclosure provides methods of treating fibrosis or a fibrotic disease or condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of cenicriviroc or a salt or solvent thereof. The fibrosis or fibrotic disease may be liver fibrosis, renal fibrosis, non-cirrhotic hepatic fibrosis, associated with non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), or emerging cirrhosis.

Abstract: Cenicriviroc (CVC) is an orally active antagonist of ligand binding to C—C chemokine receptor type 5 (CCR5) and C—C chemokine receptor type 2 (CCR2). CVC blocks the binding of RANTES, MIP-1?, and MIP-1? to CCR5, and of MCP-1/CCL2 to CCR2. Methods of treating fibrosis and related conditions comprising co-administration of CVC with chemokine antagonists, FXR agonists, high dose vitamin E (>400 iU/d), a peroxisome proliferator-activated receptor alpha (PPAR-?) agonist, PPAR-? agonist, and/or PPAR-? agonist are provided herein.

Abstract: A method for transforming and routing data includes receiving data from one of a number of remote computing systems. The data is in the form of a first data format associated with a legacy processing system. Source information related to the one of the plurality of remote computing systems is identified. A determination is made that the one of the plurality of remote computing systems has been migrated to a new processing system based at least in part on the source information. The data is mapped to a second data format associated with the new processing system. A transmission is routed to the new processing system. The transmission includes the mapped data in the form of the second data format.

Abstract: The disclosure includes the use of cenicriviroc or a salt or solvate thereof and pharmaceutical compositions containing the same in the treatment of inflammation and connective tissue diseases and disorders, such as fibrosis, peritonitis, and liver injury.